SCHEMBL31713402

SCHEMBL31713402

Cc1ccc(S(=O)(=O)n2nc(N3CCN(c4ncc(Cl)cc4F)CC34CC4)c3c(Cl)cc(F)cc32)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.38
BCR P11274 2/20 0.38
HSD11B1 P28845 5/20 0.36
GBA1 P04062 4/20 0.36
ALDH1A1 P00352 4/20 0.34
KDM4E B2RXH2 3/20 0.34
NPSR1 Q6W5P4 3/20 0.34
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34
MAPK1 P28482 2/20 0.34
GAA P10253 2/20 0.34
TP53 P04637 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
APAF1 O14727 1/20 0.34
HTT P42858 2/20 0.33
RAB9A P51151 1/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KMT2A Q03164 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31713789 0.94 ABL1 (0.38) ABL1BCRHSD11B1GBA1ALDH1A1
SCHEMBL31713632 0.92 HSD11B1 (0.38) ABL1BCRHSD11B1GBA1ALDH1A1
SCHEMBL31713705 0.91 ABL1 (0.38) ABL1BCRHSD11B1GBA1ALDH1A1
SCHEMBL31713691 0.91 ABL1 (0.39) ABL1BCRHSD11B1GBA1ALDH1A1
SCHEMBL31713329 0.90 HSD11B1 (0.44) ABL1BCRHSD11B1GBA1ALDH1A1
SCHEMBL31713321 0.89 ABL1 (0.37) ABL1BCRHSD11B1GBA1ALDH1A1
SCHEMBL31713749 0.88 ABL1 (0.36) ABL1BCRHSD11B1GBA1ALDH1A1
SCHEMBL31713377 0.88 ABL1 (0.39) ABL1BCRHSD11B1GBA1ALDH1A1
SCHEMBL31713368 0.88 PIK3CA (0.35) ABL1BCRHSD11B1GBA1ALDH1A1
SCHEMBL31713493 0.87 ABL1 (0.38) ABL1BCRHSD11B1GBA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333406-A1 SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYSOWAY THERAPEUTICS INC (US) 2025-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333406-A1 SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF STOML2, ATP2A3, ATP2A1 ABL1 4069/4885BCR 282/4885HSD11B1 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.